Elio Monsour

Elio Monsour

Auto-generated profile, based on publicly available information

Elio Monsour

University of Central Florida, Ocala, FL, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2021 in Journal of Diabetes & Metabolic Disorders
Verified
Journal Article
Closed access
PDF file
EMElio Monsour
Elio Monsour
LRLyd-Marie Rodriguez
Lyd-Marie Rodriguez
RARanda Abdelmasih
Randa Abdelmasih
KTKubra Tuna
Kubra Tuna
KAKhalid Abusaada
Khalid Abusaada

2 September 2020 in Cureus
Verified
Journal Article
Open access
PDF file
EHEthan N. Hartman
Ethan N. Hartman
KTKubra Tuna
Kubra Tuna
EMElio Monsour
Elio Monsour
KKKarthikram Komanduri
Karthikram Komanduri
ATAneta Tarasiuk-Rusek
Aneta Tarasiuk-Rusek
Posterior reversible encephalopathy syndrome (PRES) is a syndrome presenting with neurological manifestations including headaches, seizures, and notable changes in brain imaging. It is typically associated with an acute increase in blood pressure, metabolic abnormalities, and/or medication effects. PRES is challenging to diagnose due to its variable presentation and low incidence. Herein we describe a compelling case of PRES syndrome secondary to uncontrolled hypertension in the setting of systemic lupus erythematosus (SLE) and lupus nephritis.

22 March 2021 in Cureus
Verified
Journal Article
Open access
RARanda Abdelmasih
Randa Abdelmasih
RARamy Abdelmaseih
Ramy Abdelmaseih
EMElio Monsour
Elio Monsour
JRJustin Reed
Justin Reed
Internal carotid artery dissection (ICAD) is a known but uncommon cause of ischemic stroke among young and middle-aged patients. A common presentation includes ipsilateral headache, unilateral oculosympathetic palsy (partial Horner syndrome), or ischemic stroke but some reported cases present with less common manifestations, such as lower cranial nerve syndrome (IX, X, XI, XII). However, third cranial nerve palsy is an extremely rare presentation of ICAD. We present a case of ICAD with pseudoaneurysm presenting with third nerve palsy, with ptosis, outward deviation, and binocular diplopia, emphasizing the importance of considering ICAD as a differential diagnosis in patients with third nerve palsy due to the anatomical proximity of ICA to third nerve within the cavernous sinus.

1 May 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
EMElio Paul Monsour
Elio Paul Monsour
RARanda Abdelmasih
Randa Abdelmasih
JPJoshua Pothen
Joshua Pothen
RGRima Gandhi
Rima Gandhi
FRFrank Ramharrack
Frank Ramharrack
Background: Metastatic pheochromocytomas are rare neuroendocrine tumors that carry a poor prognosis. There are no curative treatments; however, current therapeutic strategies to control tumor burden include surgery, radiation, ablative therapy, chemoembolization, and systemic therapies. We describe an interesting case of a patient with metastatic pheochromocytoma misdiagnosed as renal cell carcinoma (RCC) started on axitinib and pembrolizumab, who achieved a partial response to treatment, despite lack of approved indications for these therapies in metastatic pheochromocytoma. Clinical Case: A 64-year-old man presented to the emergency department (ED) with uncontrolled hypertension and severe headache. A 12 cm left-sided pheochromocytoma was diagnosed 11 years ago, which was surgically resected via adrenalectomy. After surgery, the patient was followed in the endocrine clinic for five years with pheochromocytoma serum biochemical markers and declared free of disease. 2 months before hospital admission, he was worked-up for flank pain and at that time, CT abdomen showed a 3 cm mass in the liver and exophytic solid mass measuring 4.2 cm off the left kidney. Subsequently, a CT guided biopsy of the left renal mass was performed and revealed grade II renal cell carcinoma (RCC). He was referred to oncology and was started on a combination of IV pembrolizumab, an immune checkpoint inhibitor against PD-1/PD-L1, and oral axitinib, a selective VEGF receptor inhibitor. He received 3 cycles of immunotherapy treatment; however, he became significantly hypertensive with intermittent headaches, so he was started on atenolol 25 mg once daily. Despite this, he continued to have uncontrolled hypertension, worsening headaches, and flushing, which prompted him to undergo evaluation in the ED. On arrival, BP was 210/90. Labs were remarkable for Hgb 17.2, WBC count of 17.1, and glucose of 178 mg/dL. CT head was negative for any acute intracranial process. Due to suspected recurrence of pheochromocytoma, atenolol was stopped, adrenal workup was conducted, and the patient was started on doxazosin. Urine metanephrines came back elevated at 1097 (RR: 55-320 μg/24 hrs), urine norepinephrine of 260 (RR: 14-120 μg/24 hrs), and urine normetanephrine of 3305 (RR: 114-865 μg/24 hrs). Re-evaluation of pathology opinion was obtained, which indicated that biopsy stained positive for chromogranin A and synaptophysin markers, consistent with metastatic pheochromocytoma. FDG PET/CT was performed following discharge, which revealed the left renal mass decreased to 2.4 cm and the liver mass shrunk to 1.5 cm. Conclusion: To our knowledge, this is the first case report outside of a clinical trial highlighting partial response to axitinib and pembrolizumab in metastatic pheochromocytoma. Emerging preliminary phase II clinical trial data are currently investigating these medications as future treatment modalities.

1 May 2021 in Journal of the Endocrine Society
Verified
Journal Article
Open access
PDF file
RARanda Abdelmasih
Randa Abdelmasih
RARamy Abdelmaseih
Ramy Abdelmaseih
EMElio Paul Monsour
Elio Paul Monsour
SHS Mustajab Hasan
S Mustajab Hasan
JVJosef James Karl Vesely
Josef James Karl Vesely
Intruducion: Secondary hyperparathyroidism (SHPT) is prevalent in patients with end-stage renal disease (ESRD) with reported prevalence of 90%. SHPT treatment is usually medical. Although 5% ends up with parathyroidectomy. Indications of parathyroidectomy in ESRD patients include persistent elevation of PTH more than 800, Calcyphylaxis, Osteitis Fibrosa Cystica, and persistent anemia. Among these patients who require surgery, 5–20% present with persistent or recurrent disease and require further re-exploration and excision of parathyroid tissue. We present a case of persistent Calciphylaxis and SHPT in ESRD patient despite Parathyroidectomy which prompted diagnosing an ectopic mediastinal parathyroid adenoma. Case Presentation: 49 year-old male with ESRD for 15 years complicated with SHPT, presented due to worsening Caciphylaxis of bilateral lower extremities despite Cinacalcet, IV sodium thiosulfate, and Phosphate binder. Serum Calcium level was 9.0 mg/dl with corrected levels of 10.2 mg/dl, Phosphorus level of 9.3 with Intact PTH level 1,369 pg/ml. Ultrasound of parathyroid glands was normal. Due to failure of medical treatment, He underwent Total parathyridectomy and left arm parathyroid autograft. Intraoperative PTH level went down to 300 (less than 50%). Calciphylaxis never improved. 5 months later, Parathyroid hormone was elevated 1338 pg/ml, Calcium level 6.9 mg/dl and Phosphorus level 10.0 mg/dl. 99mTc-sestamibi parathyroid scan didn’t show any activity in thyroid gland area and no increased uptake at the autograft area. Although it showed a small focus of persistent activity in substernal area suggestive of ectopic parathyroid tissue. Patient was referred for removal of ectopic adenoma. Discussion: Persistent SHPT is identified as the persistence or recurrence of symptoms, lab abnormalities and radiologic findings within 6 months after parathyroidectomy. Pathophysiology of recurrence is not well studied but one theory suggests that in SHPT, altered Calcium-phosphate hemostasis leads to hyperplasia of parathyroid tissue including ectopic and supernumerary tissue. This aforementioned altered hemostasis continues even after parathyroidectomy and cause hyperplasia and hyperfunction of the residual parathyroid tissue left accidentally by seeding within surgical site or implanted autograft or It can present with ectopic adenoma, even if they were undetected prior to or in the first intervention. Ectopic parathyroid tissue is an uncommon etiology of persistent or recurrent secondary hyperparathyroidism, it is reported in many cases where it was missed at initial workup. Prevalence reported up to 14% in patients with persistent SHPT. It is warranted further investigations to look for ectopic parathyroid tissue in patients with ESRD who present with recurrent or persistent secondary hyperparathyroidism after total parathyroidectomy with reimplantation.

29 November 2022 in JCEM Case Reports
Verified
Journal Article
Open access
PDF file
EMElio Monsour
Elio Monsour
SBSanaa Badour
Sanaa Badour
SKSushma Kadiyala
Sushma Kadiyala
MXMajlinda Xhikola
Majlinda Xhikola
A 61-year-old man with osteopetrosis since birth presented to establish care. Complications included severe sensorineural hearing loss, nephrolithiasis, anemia,